Cargando…

Indolent thyroid cancer: knowns and unknowns

Thyroid cancer incidence is rapidly increasing due to increased detection and diagnosis of indolent thyroid cancer, i.e. cancer that is likely to be clinically insignificant. Clinical, radiologic, and pathologic features predicting indolent behavior of thyroid cancer are still largely unknown and un...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn, Lewis D., Kunder, Christian A., Chen, Michelle M., Orloff, Lisa A., Desser, Terry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460732/
https://www.ncbi.nlm.nih.gov/pubmed/31093348
http://dx.doi.org/10.1186/s41199-016-0021-x
_version_ 1783410372034691072
author Hahn, Lewis D.
Kunder, Christian A.
Chen, Michelle M.
Orloff, Lisa A.
Desser, Terry S.
author_facet Hahn, Lewis D.
Kunder, Christian A.
Chen, Michelle M.
Orloff, Lisa A.
Desser, Terry S.
author_sort Hahn, Lewis D.
collection PubMed
description Thyroid cancer incidence is rapidly increasing due to increased detection and diagnosis of indolent thyroid cancer, i.e. cancer that is likely to be clinically insignificant. Clinical, radiologic, and pathologic features predicting indolent behavior of thyroid cancer are still largely unknown and unstudied. Existing clinicopathologic staging systems are useful for providing prognosis in the context of treated thyroid cancer but are not designed for and are inadequate for predicting indolent behavior. Ultrasound studies have primarily focused on discrimination between malignant and benign nodules; some studies show promising data on using sonographic features for predicting indolence but are still in their early stages. Similarly, molecular studies are being developed to better characterize thyroid cancer and improve the yield of fine needle aspiration biopsy, but definite markers of indolent thyroid cancer have yet to be identified. Nonetheless, active surveillance has been introduced as an alternative to surgery in the case of indolent thyroid microcarcinoma, and protocols for safe surveillance are in development. As increased detection of thyroid cancer is all but inevitable, increased research on predicting indolent behavior is needed to avoid an epidemic of overtreatment.
format Online
Article
Text
id pubmed-6460732
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64607322019-05-15 Indolent thyroid cancer: knowns and unknowns Hahn, Lewis D. Kunder, Christian A. Chen, Michelle M. Orloff, Lisa A. Desser, Terry S. Cancers Head Neck Review Thyroid cancer incidence is rapidly increasing due to increased detection and diagnosis of indolent thyroid cancer, i.e. cancer that is likely to be clinically insignificant. Clinical, radiologic, and pathologic features predicting indolent behavior of thyroid cancer are still largely unknown and unstudied. Existing clinicopathologic staging systems are useful for providing prognosis in the context of treated thyroid cancer but are not designed for and are inadequate for predicting indolent behavior. Ultrasound studies have primarily focused on discrimination between malignant and benign nodules; some studies show promising data on using sonographic features for predicting indolence but are still in their early stages. Similarly, molecular studies are being developed to better characterize thyroid cancer and improve the yield of fine needle aspiration biopsy, but definite markers of indolent thyroid cancer have yet to be identified. Nonetheless, active surveillance has been introduced as an alternative to surgery in the case of indolent thyroid microcarcinoma, and protocols for safe surveillance are in development. As increased detection of thyroid cancer is all but inevitable, increased research on predicting indolent behavior is needed to avoid an epidemic of overtreatment. BioMed Central 2017-01-11 /pmc/articles/PMC6460732/ /pubmed/31093348 http://dx.doi.org/10.1186/s41199-016-0021-x Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Hahn, Lewis D.
Kunder, Christian A.
Chen, Michelle M.
Orloff, Lisa A.
Desser, Terry S.
Indolent thyroid cancer: knowns and unknowns
title Indolent thyroid cancer: knowns and unknowns
title_full Indolent thyroid cancer: knowns and unknowns
title_fullStr Indolent thyroid cancer: knowns and unknowns
title_full_unstemmed Indolent thyroid cancer: knowns and unknowns
title_short Indolent thyroid cancer: knowns and unknowns
title_sort indolent thyroid cancer: knowns and unknowns
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460732/
https://www.ncbi.nlm.nih.gov/pubmed/31093348
http://dx.doi.org/10.1186/s41199-016-0021-x
work_keys_str_mv AT hahnlewisd indolentthyroidcancerknownsandunknowns
AT kunderchristiana indolentthyroidcancerknownsandunknowns
AT chenmichellem indolentthyroidcancerknownsandunknowns
AT orlofflisaa indolentthyroidcancerknownsandunknowns
AT desserterrys indolentthyroidcancerknownsandunknowns